• 9964432222
  • Mail Us
  • Appointment
  • Locate Us
  • Chat Now
  • Courses
  • Login
  • Register
Manifest IAS
JournalsOfIndia
Advertisement
  • Home
  • Economy
  • Foreign Affairs
  • Science & Tech
  • Environment
  • Law & Policy
  • History
No Result
View All Result
  • Home
  • Economy
  • Foreign Affairs
  • Science & Tech
  • Environment
  • Law & Policy
  • History
No Result
View All Result
  • 9964432222
  • Mail Us
  • Appointment
  • Locate Us
  • Chat Now
  • Courses
JournalsOfIndia
No Result
View All Result
Home Science & Tech

What is Emergency Use Approval of a Vaccine?

December 9, 2020
in Science & Tech, Law & Policy
Reading Time: 3min read
0
What is Emergency Use Approval of a Vaccine?
0
SHARES
100
VIEWS
Share on TelegramShare on Facebook

In news

Recently, the USA’s drug maker Moderna said it was applying for emergency use authorization for its COVID vaccine.  

What is Emergency Use Approval/Authorization (EUA)of a Vaccine?

  • It is a mechanism to facilitate the availability and use of medical countermeasures, including vaccines, during public health emergencies, such as the current COVID-19 pandemic
  • In India such authorization is given by the Central Drugs Standard Control Organisation (CDSCO).

Is approval necessary & what is the process?

  • Vaccines and medicines, and even diagnostic tests and medical devices, require the approval of a regulatory authority before they can be administered.
  • With respect to  vaccines and medicines, approval is granted after an assessment of their safety and effectiveness, based on data from trials. 
  • The approval from the regulator is required at every stage of these trials. 
  • It’s  a long process, designed to ensure that a medicine or vaccine is absolutely safe and effective. 
  • The fastest approval for any vaccine until now — the mumps vaccine in the 1960s — took about four-and-a-half years after it was developed.
  • During the emergency situations, like the current one, regulatory authorities around the world have developed mechanisms to grant interim approvals if there is sufficient evidence to suggest a medical product is safe and effective. 
  • Final approval is granted only after completion of the trials and analysis of full data; until then, emergency use authorization allows the medicine or the vaccine to be used on the public.

When can emergency use authorization be granted?

  • In the USA, the Food and Drug Administration (FDA) grants an EUA only after it has been determined that the “known and potential benefits outweigh the known and potential risks of the vaccine” (or medicine).
  • It means that an EUA application can be considered only after sufficient efficacy data from phase 3 trials had been generated

Regulatory provisions for the approval of vaccines in India: 

  • In India, Clinical trials of new drugs and vaccines, and their approvals, are governed by the New Drugs and Clinical Trials Rules(NDCT), 2019.
  • But, these Rules do not use the term “emergency use authorisation”. 
  • This term is used mainly by the regulatory agencies in the US and some other countries, and has become popular in the context of the current epidemic. 
  • However, that does not mean that the Indian regulatory system does not have provisions for “special situations” like the current one.
  • The NDCT rules 2019 provide for an “accelerated approval process” in several situations that would include the one like the current pandemic.
  • In such situations, there is a provision for granting approval to a drug that is still in clinical trials, “provided there is a prima facie case of the product being of meaningful therapeutic benefit”.
  • Provisions of these rules says that “Accelerated approval may also be granted to a new drug if it is intended for the treatment of a serious, or life-threatening condition, or disease of special relevance to the country, and addresses unmet medical needs,”. The definition of new drug in the 2019 Rules includes a vaccine.
  • Further,the new rules make it clear that a new drug, or a vaccine, can be considered for approval if “remarkable” effectiveness is reported even from phase-II trials.
  • Provided, the remarkable efficacy is observed with a defined dose in the phase-II clinical trials of the investigational new drug for the unmet medical needs of serious and life threatening disease in the country, it may be considered for grant of marketing approval by the central licensing authority based on phase-II clinical trial data. 
  • In such cases, additional post licensure studies may be required to be conducted after approval to generate the data on larger population
  • Therefore, the approval granted to drugs or vaccines that are still in clinical trials is temporary, and valid only for one year. 
Source: The Indian Express
Tags: PRELIMS

Related Posts

Tejas 1A

Tejas 1A

January 15, 2021
e-Kranti

e-Kranti

January 15, 2021
Deendayal Disabled Rehabilitation Scheme

Deendayal Disabled Rehabilitation Scheme

January 15, 2021
Right of Persons with Disabilities Act, 2016

Right of Persons with Disabilities Act, 2016

January 15, 2021
UN Convention Right of Person with Disability(UNCRPD)

UN Convention Right of Person with Disability(UNCRPD)

January 15, 2021
Swachh Bharat Mission Urban

Swachh Bharat Mission Urban

January 15, 2021
National Innovation Foundation

National Innovation Foundation

January 15, 2021
Vigyan Jyoti and Engage with Science (Vigyan Prasar)

Vigyan Jyoti and Engage with Science (Vigyan Prasar)

January 14, 2021
Medical Model of Disability Vs  Social Model of Disability

Medical Model of Disability Vs Social Model of Disability

January 14, 2021
Antodaya Anna Yojana

Antodaya Anna Yojana

January 14, 2021
Please login to join discussion

Browse by Category

  • Agriculture
  • Disaster Management
  • Economy
  • Environment
  • Ethics
  • Foreign Affairs
  • Geography
  • Governance
  • History
  • Law & Policy
  • Opinion
  • People in News
  • Places in News
  • Science & Tech
  • Security
  • Society

Browse by Tags

BIG PICTURE GS-1 GS-2 GS-3 GS-4 KURUKSHTERA MAINS NEWS PAPER PIB PRELIMS RSTV YOJANA
JournalsOfIndia

Our vision is to orient the readers to grasp the facts objectively and analyse critically. In the rush of reaching first to the readers, the websites miss the balanced opinion, which is the need of the hour. We aim to reach the readers with more crispness, preciseness and relevance. We bring the articles in UPSC way for the civil services aspirants and the Wisest Way for general readers.

Categories

  • Agriculture
  • Disaster Management
  • Economy
  • Environment
  • Ethics
  • Foreign Affairs
  • Geography
  • Governance
  • History
  • Law & Policy
  • Opinion
  • People in News
  • Places in News
  • Science & Tech
  • Security
  • Society

Browse by Tag

BIG PICTURE GS-1 GS-2 GS-3 GS-4 KURUKSHTERA MAINS NEWS PAPER PIB PRELIMS RSTV YOJANA

Newsletter

The most important UPSC news and events of the day.

Get Journals daily newsletter on your inbox.

© 2020 JournalsOfIndia - A free initiative by Manifest Team.

  • Login
  • Sign Up
  • Home
  • Prelims Snippets
  • Mains Articles
  • Economy
  • Society
  • Foreign Affairs
  • Science & Tech
  • Environment
  • Agriculture
  • History
  • Law & Policy
  • Security
  • Course Portal
  • Prelims Test Portal
No Result
View All Result

© 2020 JournalsOfIndia - A free initiative by Manifest Team.

Welcome Back!

Login to your account below

Forgotten Password? Sign Up

Create New Account!

Fill the forms bellow to register

All fields are required. Log In

Retrieve your password

Please enter your username or email address to reset your password.

Log In